Related Experiment Videos
[Management of multiple myeloma]
F Di Raimondo1, A Pennisi, A Bari
1Divisione Clinicizzata di Ematologia, Ospedale Ferrarotto, Catania. diraimon@unict.it
Summary
Multiple myeloma (MM) is an incurable blood cancer. While traditional chemotherapy offers limited survival benefits, new targeted therapies show promise for improved outcomes.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Context:
- Multiple myeloma (MM) is a progressive plasma cell malignancy with a median survival of 36-60 months with conventional chemotherapy.
- Monoclonal gammopathy of undetermined significance (MGUS) has a 0.6-3% annual progression rate to MM.
- Current MM treatments include glucocorticoids, cytotoxic chemotherapeutics (e.g., Melphalan and Prednisone), and the VAD regimen for transplant candidates.
Purpose:
- To review the evolution of multiple myeloma treatment strategies.
- To highlight the role of thalidomide and emerging targeted therapies.
- To discuss the impact of understanding MM pathogenesis on treatment paradigms.
Summary:
- Conventional chemotherapy for multiple myeloma (MM) provides limited survival benefits.
- Thalidomide, alone or with steroids, demonstrates significant activity in MM management.
- New therapeutic strategies target the bone marrow microenvironment to overcome drug resistance and improve patient outcomes.
Impact:
- Advances in understanding MM pathogenesis are leading to novel treatment paradigms.
- Clinical trials indicate improved tolerability and efficacy of new MM agents.
- Targeted therapies offer a promising framework for enhancing patient outcomes in multiple myeloma.